Movement Alert｜Danaher Rises 3.22% in Regular Trading, RBC Capital Markets Bullish on Bioprocess Recovery Outlook

Market Focus05-19 22:07

On May 15, Danaher rose 3.22% in regular trading, trading at $169.385/share, with trading volume of $136 million. The stock was buoyed by a bullish research note from RBC Capital Markets highlighting improving bioprocess demand trends.

RBC Capital Markets indicated that Danaher could see approximately 6% revenue growth in 2027, driven by a rebound in bioprocess demand and improving end markets. The firm's channel checks revealed robust demand trends for bioprocess consumables and expanding equipment order pipelines. With bioprocessing representing more than 25% of Danaher's total revenue, the company is well-positioned to benefit significantly from the sector recovery. RBC also noted that Danaher is working to close menu gaps in its Beckman Coulter business, sees continued improvement in molecular diagnostics, and could realize further growth upside from its pending Masimo acquisition expected to close in the second half of the year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128546214?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-19 22:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128546214","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Danaher Rises 3.22% in Regular Trading, RBC Capital Markets Bullish on Bioprocess Recovery Outlook","media":"Market Focus","content":"<p><p>On May 15, Danaher rose 3.22% in regular trading, trading at $169.385/share, with trading volume of $136 million. The stock was buoyed by a bullish research note from RBC Capital Markets highlighting improving bioprocess demand trends.</p><p>RBC Capital Markets indicated that Danaher could see approximately 6% revenue growth in 2027, driven by a rebound in bioprocess demand and improving end markets. The firm's channel checks revealed robust demand trends for bioprocess consumables and expanding equipment order pipelines. With bioprocessing representing more than 25% of Danaher's total revenue, the company is well-positioned to benefit significantly from the sector recovery. RBC also noted that Danaher is working to close menu gaps in its Beckman Coulter business, sees continued improvement in molecular diagnostics, and could realize further growth upside from its pending Masimo acquisition expected to close in the second half of the year.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Danaher Rises 3.22% in Regular Trading, RBC Capital Markets Bullish on Bioprocess Recovery Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Danaher Rises 3.22% in Regular Trading, RBC Capital Markets Bullish on Bioprocess Recovery Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-19 22:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 15, Danaher rose 3.22% in regular trading, trading at $169.385/share, with trading volume of $136 million. The stock was buoyed by a bullish research note from RBC Capital Markets highlighting improving bioprocess demand trends.</p><p>RBC Capital Markets indicated that Danaher could see approximately 6% revenue growth in 2027, driven by a rebound in bioprocess demand and improving end markets. The firm's channel checks revealed robust demand trends for bioprocess consumables and expanding equipment order pipelines. With bioprocessing representing more than 25% of Danaher's total revenue, the company is well-positioned to benefit significantly from the sector recovery. RBC also noted that Danaher is working to close menu gaps in its Beckman Coulter business, sees continued improvement in molecular diagnostics, and could realize further growth upside from its pending Masimo acquisition expected to close in the second half of the year.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DHR","symbol_name":"丹纳赫","start_time":0,"source_url":"","article_id":"1128546214","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128546214","pubTimestamp":1779199637,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 15, Danaher rose 3.22% in regular trading, trading at $169.385/share, with trading volume of $136 million. The stock was buoyed by a bullish research note from RBC Capital Markets highlighting...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DHR":"丹纳赫"},"translate_title":"动向提示|丹纳赫常规交易涨3.22%加拿大皇家银行资本市场看好生物工艺复苏前景","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DHR":1},"content_text":"On May 15, Danaher rose 3.22% in regular trading, trading at $169.385/share, with trading volume of $136 million. The stock was buoyed by a bullish research note from RBC Capital Markets highlighting improving bioprocess demand trends.RBC Capital Markets indicated that Danaher could see approximately 6% revenue growth in 2027, driven by a rebound in bioprocess demand and improving end markets. The firm's channel checks revealed robust demand trends for bioprocess consumables and expanding equipment order pipelines. With bioprocessing representing more than 25% of Danaher's total revenue, the company is well-positioned to benefit significantly from the sector recovery. RBC also noted that Danaher is working to close menu gaps in its Beckman Coulter business, sees continued improvement in molecular diagnostics, and could realize further growth upside from its pending Masimo acquisition expected to close in the second half of the year.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128546214","isCrawlerRequest":true}